Enzyme-Linked Immunosorbent Assay for Measurement of Cytomegalovirus Glycoprotein B Antibody in Serum
Authors:
- 1 May 2010
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 17 (5) , 836-839
Abstract
Measurement of antibody to cytomegalovirus (CMV) glycoprotein B (gB) is valuable in the assessment of the antibody response to infection and to gB-containing vaccines. For this purpose, an enzyme-linked immunosorbent assay (ELISA) with a recombinant CMV gB molecule as the antigen was evaluated. Sera from 168 anti-CMV IgG-positive and 100 seronegative subjects were used to evaluate the anti-gB antibody assay. A cutoff optical density (OD) that would distinguish gB antibody-positive from -negative sera was established. Titers of antibody to gB determined by endpoint dilution were compared with those calculated using regression analysis. The run-to-run and interoperator reproducibilities of results were measured. The mean OD + 5 standard deviations from 50 anti-CMV IgG antibody-negative sera (0.2472) was used as the cutoff between anti-gB antibody-positive and -negative results. All sera from 100 anti-CMV IgG-seronegative subjects were negative for antibody to gB. All but 1 of 168 sera from seropositive subjects were positive for antibody to gB. Observed antibody levels based on titration to the endpoint were very similar to results calculated using linear regression. The run-to-run consistency of endpoints was excellent, with 38 runs from one operator and 48 runs from another all giving results within 1 dilution of the mean value for each of three anti-CMV IgG antibody-positive serum pools. The geometric mean titer of antibody to gB for 99 sera from seropositive blood donors was 1/10,937. This ELISA gives accurate and reproducible results for the relative quantity of anti-CMV gB IgG in serum over a wide range of antibody levels.Keywords
This publication has 15 references indexed in Scilit:
- Vaccine Prevention of Maternal Cytomegalovirus InfectionNew England Journal of Medicine, 2009
- Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult SubjectsThe Journal of Infectious Diseases, 2008
- Cellular and Humoral Immune Responses to Alphavirus Replicon Vaccines Expressing Cytomegalovirus pp65, IE1, and gB ProteinsClinical and Vaccine Immunology, 2007
- Effect of Previous or Simultaneous Immunization with Canarypox Expressing Cytomegalovirus (CMV) Glycoprotein B (gB) on Response to Subunit gB Vaccine plus MF59 in Healthy CMV‐Seronegative AdultsThe Journal of Infectious Diseases, 2002
- Effects of Antigen Dose and Immunization Regimens on Antibody Responses to a Cytomegalovirus Glycoprotein B Subunit VaccineThe Journal of Infectious Diseases, 1999
- A Subunit Cytomegalovirus Vaccine Based on Recombinant Envelope Glycoprotein B and a New AdjuvantThe Journal of Infectious Diseases, 1999
- Function of Human Cytomegalovirus Glycoprotein B: Syncytium Formation in Cells Constitutively Expressing gB Is Blocked by Virus-Neutralizing AntibodiesVirology, 1994
- Glycoprotein B of Human Cytomegalovirus Promotes Virion Penetration into Cells, Transmission of Infection from Cell to Cell, and Fusion of Infected CellsVirology, 1993
- Initiation of Human Cytomegalovirus Infection Requires Initial Interaction with Cell Surface Heparan SulfateVirology, 1993
- Antibodies to Recombinant-Derived Glycoprotein B after Natural Human Cytomegalovirus Infection Correlate with Neutralizing ActivityThe Journal of Infectious Diseases, 1992